On 15 April 2026, Scientific Committee on Consumer Safety (SCCS) published its preliminary opinion (SCCS/1688/26) on the safety of Heliotropin (CAS No. 120-57-0) used in cosmetic products, following a request from the European Commission. The opinion, adopted on 26 March 2026, evaluates potential risks to human health, particularly in light of its possible classification as a reproductive toxicant category 1B under the Regulation (EC) No 1272/2008. Based on the data submitted and its scientific assessment, the SCCS concluded that heliotropin can be considered safe when used at concentrations up to 1.8% exclusively in fine fragrances intended for adult consumers. This conclusion reflects a cautious approach due to concerns regarding potential reproductive toxicity, ensuring that exposure scenarios remain within acceptable safety margins. The SCCS did not propose alternative safe concentration limits for broader cosmetic uses beyond this specific application. Furthermore, no additional scientific concerns were identified within the scope of the submitted data, although the assessment remains limited to the evaluated use conditions. A public consultation on the preliminary opinion is open until 15 June 2026, allowing stakeholders to provide comments and additional scientific evidence. The outcome will inform future regulatory considerations under Regulation (EC) No 1223/2009, supporting risk management decisions for fragrance ingredients in cosmetic products across the European Union.
Consumer News Region